Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
27 Oct 2023 07:00 AM
RNS
Block Listing Six Monthly Return
23 Oct 2023 01:30 PM
RNS
Issue of Equity and Total Voting Rights
18 Oct 2023 01:00 PM
RNS
Block Listing Application to AIM
05 Oct 2023 07:00 AM
RNS
Avacta to present at AACR-NCI-EORTC conference
29 Sep 2023 01:30 PM
RNS
Director/PDMR Shareholding
28 Sep 2023 07:00 AM
RNS
Interim Results for the Period Ending 30 June 2023
20 Sep 2023 02:00 PM
RNS
Issue of Equity and Total Voting Rights
20 Sep 2023 07:01 AM
RNS
Peel Hunt Appointed as Joint Broker
20 Sep 2023 07:00 AM
RNS
Appointment Dr.Christina Coughlin as a consultant
19 Sep 2023 07:00 AM
RNS
Successful Completion of Sixth Dose Escalation
06 Sep 2023 07:00 AM
RNS
Notice of Results
21 Jul 2023 03:00 PM
RNS
Issue of Equity and Total Voting Rights
28 Jun 2023 11:00 AM
RNS
Result of Annual General Meeting
28 Jun 2023 07:00 AM
RNS
Annual General Meeting and Shareholder Event
21 Jun 2023 07:00 AM
RNS
Completion of Fifth Dose Escalation in AVA6000
19 Jun 2023 07:01 AM
RNS
Director Appointment
19 Jun 2023 07:00 AM
RNS
Statement regarding market speculation
08 Jun 2023 07:00 AM
RNS
AGM and Shareholder Event Detailed Agenda
05 Jun 2023 07:00 AM
RNS
Second Milestone in AffyXell Joint Venture
02 Jun 2023 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
01 Jun 2023 07:00 AM
RNS
Avacta acquires Coris Bioconcept
27 Apr 2023 07:00 AM
RNS
Block Listing Six Monthly Return
27 Apr 2023 07:00 AM
RNS
First Patient Dosed in the US in AVA6000 Phase 1
25 Apr 2023 07:00 AM
RNS
Preliminary Results
25 Apr 2023 07:00 AM
RNS
Preliminary Results
21 Apr 2023 02:49 PM
RNS
Issue of Equity and Total Voting Rights
21 Apr 2023 02:49 PM
RNS
Issue of Equity and Total Voting Rights
17 Apr 2023 07:00 AM
RNS
AVA3996 data poster presented at AACR
06 Apr 2023 07:00 AM
RNS
1st US Clinical Investigator AVA6000 Sites Opened
05 Apr 2023 07:00 AM
RNS
First Patient Dosed in Fifth Cohort of AVA6000
03 Apr 2023 07:00 AM
RNS
Notice of Results and Investor Presentation
27 Mar 2023 07:00 AM
RNS
AVA3996 data poster presentation at AACR
13 Mar 2023 07:00 AM
RNS
Statement re: Silicon Valley Bank
23 Feb 2023 07:00 AM
RNS
Avacta Therapeutics Division Science Day
13 Feb 2023 07:00 AM
RNS
Issue of Equity and Total Voting Rights
23 Jan 2023 12:20 PM
RNS
Issue of Equity and Total Voting Rights
17 Jan 2023 02:05 PM
RNS
Second Price Monitoring Extn
17 Jan 2023 02:00 PM
RNS
Price Monitoring Extension
17 Jan 2023 11:05 AM
RNS
Second Price Monitoring Extn
17 Jan 2023 11:00 AM
RNS
Price Monitoring Extension
17 Jan 2023 09:05 AM
RNS
Second Price Monitoring Extn
17 Jan 2023 09:00 AM
RNS
Price Monitoring Extension
17 Jan 2023 07:00 AM
RNS
Successful Completion of Fourth Dose Escalation
16 Jan 2023 10:15 AM
RNS
Block Listing Application to AIM
19 Dec 2022 07:00 AM
RNS
Avacta to Host Therapeutics Division Science Day
08 Nov 2022 07:01 AM
RNS
Director/PDMR Shareholding
08 Nov 2022 07:00 AM
RNS
Result of the Open Offer
31 Oct 2022 01:32 PM
RNS
Avacta to Present at Theranostics FAP Summit
31 Oct 2022 11:05 AM
RNS
Second Price Monitoring Extn
31 Oct 2022 11:00 AM
RNS
Price Monitoring Extension

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100